- Home
- BCLI vs NXL Comparison
BCLI vs NXL Comparison
Compare BCLI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- NXL
- Stock Information
- Founded
- BCLI 2000
- NXL 2010
- Country
- BCLI United States
- NXL United States
- Employees
- BCLI N/A
- NXL N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- NXL Medical Specialities
- Sector
- BCLI Health Care
- NXL Health Care
- Exchange
- BCLI Nasdaq
- NXL Nasdaq
- Market Cap
- BCLI 9.1M
- NXL 10.0M
- IPO Year
- BCLI N/A
- NXL 2022
- Fundamental
- Price
- BCLI $2.25
- NXL $3.23
- Analyst Decision
- BCLI Strong Buy
- NXL Hold
- Analyst Count
- BCLI 1
- NXL 1
- Target Price
- BCLI $30.00
- NXL N/A
- AVG Volume (30 Days)
- BCLI 112.8K
- NXL 533.6K
- Earning Date
- BCLI 11-14-2024
- NXL 11-08-2024
- Dividend Yield
- BCLI N/A
- NXL N/A
- EPS Growth
- BCLI N/A
- NXL N/A
- EPS
- BCLI N/A
- NXL N/A
- Revenue
- BCLI N/A
- NXL $162,078.00
- Revenue This Year
- BCLI N/A
- NXL $56.86
- Revenue Next Year
- BCLI N/A
- NXL $167.44
- P/E Ratio
- BCLI N/A
- NXL N/A
- Revenue Growth
- BCLI N/A
- NXL 26.00
- 52 Week Low
- BCLI $1.05
- NXL $0.25
- 52 Week High
- BCLI $11.85
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- BCLI 70.03
- NXL 42.43
- Support Level
- BCLI $1.45
- NXL $3.25
- Resistance Level
- BCLI $1.72
- NXL $4.49
- Average True Range (ATR)
- BCLI 0.18
- NXL 0.35
- MACD
- BCLI 0.08
- NXL -0.17
- Stochastic Oscillator
- BCLI 84.69
- NXL 7.26
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.